IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. 10 stocks we like better than Eli Lilly ...

Eli Lilly is the current leader in the GLP-1 weight-loss drug space. Investors have placed a high valuation on Lilly's stock. Pfizer could be a more attractive option for long-term investors who love ...

Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.

In the lucrative obesity drug race, there is Eli Lilly — and then there's everybody else. A pair of headlines Monday reinforced Lilly's dominance: Its lone commercial rival, Novo Nordisk , released ...

Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...